Antigen News and Research

RSS

Genalyte receives NCI grant to develop biomarker panel to profile TAA autoantibodies

Genalyte, Inc., today announced that it has received a $1 million SBIR grant from the National Cancer Institute to develop a biomarker panel to profile tumor antigen-associated autoantibodies.

18 Oct 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

GenSpera to present G-202 Phase I trial in hepatocellular carcinoma at EORTC-NCI-AACR Symposium

GenSpera, Inc. (OTCBB:GNSZ) announced that Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma, will present data from the G-202 Phase I clinical trial at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, MA on Monday, October 21st.

18 Oct 2013

Imaxio Sells Genomics Division To Hybrigenics

...

16 Oct 2013

Simple blood test can help diagnose early-stage lung and prostate cancers

Early-stage lung and prostate cancers as well as their recurrence can be detected with a simple blood test, according to a study presented at the ANESTHESIOLOGY 2013 annual meeting.

16 Oct 2013

UTMB researchers find high variability in PSA-ordering practice among primary care physicians

Many primary care doctors continue to administer the prostate-specific antigen test to even their oldest patients despite the fact that no medical organization recommends prostate cancer screening for men older than 75, according to new research from the University of Texas Medical Branch at Galveston.

15 Oct 2013

House dust mite allergy treatment: an interview with Steve Harris, CEO & Co-founder of Circassia

House dust mite allergy is a surprisingly prevalent problem. Something like 27% of the U.S. population and 20% of the European population are what’s called skin-prick test positive for house dust mites, which is a test for sensitivity to allergens to find out if a person is likely to get that allergy.

15 Oct 2013

Promising new type of cancer treatment to benefit more patients

More patients than ever stand to benefit from a promising new type of cancer treatment, after scientists compiled a library of molecules that can prime patients’ immune systems to fight a range of cancers including leukaemia, myeloma, lung cancer and skin cancer.

15 Oct 2013

Bladder involvement can lead to prostate cancer misdiagnosis

Men with lesions in the neck, trigone, or posterior wall of the bladder should be tested for basal prostate cancer as well as bladder cancer to ensure that they are not misdiagnosed, say researchers.

14 Oct 2013

Football-shaped artificial particles teach immune cells to recognize, destroy cancer cells

Researchers at Johns Hopkins have succeeded in making flattened, football-shaped artificial particles that impersonate immune cells. These football-shaped particles seem to be better than the typical basketball-shaped particles at teaching immune cells to recognize and destroy cancer cells in mice.

14 Oct 2013

Study evaluates possibility of individualisation of castration-resistant prostate cancer management

A new study reveals that in the prediction of treatment outcome for castration-resistant prostate cancer, a change in circulating tumour cells detection might be more accurate than the change in prostate-specific antigen levels. The findings of this award-winning study were presented at the recent EAU 13th Central European Meeting in Prague.

12 Oct 2013

New gene transfer strategy effective for achieving persistent immunotherapy to treat tumors

Cancer immunotherapy can successfully use the body's own immune system to kill tumor cells. But some current approaches to stimulate an antitumor immune response are short-lived, with limited clinical effectiveness. A new gene transfer strategy that introduces modified, immune-stimulating human stem cells is both feasible and effective for achieving persistent immunotherapy to treat leukemias and lymophomas, according to a study published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

11 Oct 2013

Heptares' StaR platform offers breakthrough solution to challenge associated with antibodies therapeutics

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, achieved the first research milestone in its antibody therapeutics alliance with MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX), announced in February 2013.

10 Oct 2013

Three Penn Medicine researchers awarded grants for neuromuscular disease research

The Muscular Dystrophy Association has awarded research grants totaling over $1,000,000 to three Penn Medicine researchers: James Shorter, PhD, associate professor of Biochemistry and Biophysics; Hansell Stedman, MD, associate professor of Surgery; and Lee Sweeney, PhD, director of the Center for Orphan Disease Research and Therapy.

9 Oct 2013

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520, its RNAi-based candidate against chronic hepatitis B virus infection.

9 Oct 2013

PSA mass ratio shows prognostic power in localized prostate cancer

Research shows that pathologic prostate-specific antigen mass ratio is a significant predictor for biochemical recurrence-free survival following radical prostatectomy for localized prostate cancer in patients with negative surgical resection margins.

8 Oct 2013

Vaccination campaign led HBV to more than double rate of "breakout" mutations

A universal infant vaccination campaign in China has led the Hepatitis B virus (HBV) to more than double its rate of "breakout" mutations. These mutations may enable the virus to elude the vaccine, necessitating new vaccination strategies.

8 Oct 2013

Immutep, Eddingpharm partner to develop and commercialize ImmuFact IMP321

Immutep S.A., the biopharmaceutical company specializing in immuno-oncology, and Eddingpharm have entered into an agreement regarding the development, commercialization and manufacturing of Immutep’s ImmuFact IMP321.

7 Oct 2013

J&J's Janssen Companies Launch A Trio Of Collaborations

...

3 Oct 2013

CureVac collaborates with Janssen on development of influenza vaccine based on mRNA

CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that it has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. Under the agreement CureVac will collaborate with Crucell Holland B.V. (a member of the Janssen Pharmaceutical Companies) on the development of an influenza vaccine based on CureVac's RNActive® technology.

3 Oct 2013

Antigen News and Research

Genalyte receives NCI grant to develop biomarker panel to profile TAA autoantibodies

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

GenSpera to present G-202 Phase I trial in hepatocellular carcinoma at EORTC-NCI-AACR Symposium

Imaxio Sells Genomics Division To Hybrigenics

Simple blood test can help diagnose early-stage lung and prostate cancers

UTMB researchers find high variability in PSA-ordering practice among primary care physicians

House dust mite allergy treatment: an interview with Steve Harris, CEO & Co-founder of Circassia

Promising new type of cancer treatment to benefit more patients

Bladder involvement can lead to prostate cancer misdiagnosis

Football-shaped artificial particles teach immune cells to recognize, destroy cancer cells

Study evaluates possibility of individualisation of castration-resistant prostate cancer management

New gene transfer strategy effective for achieving persistent immunotherapy to treat tumors

Heptares' StaR platform offers breakthrough solution to challenge associated with antibodies therapeutics

Three Penn Medicine researchers awarded grants for neuromuscular disease research

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

PSA mass ratio shows prognostic power in localized prostate cancer

Vaccination campaign led HBV to more than double rate of "breakout" mutations

Immutep, Eddingpharm partner to develop and commercialize ImmuFact IMP321

J&J's Janssen Companies Launch A Trio Of Collaborations

CureVac collaborates with Janssen on development of influenza vaccine based on mRNA

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News